CR9266A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Info

Publication number: CR9266A
Authority: CR; Costa Rica
Prior art keywords: glucagon; compositions; methods; similar; peptide agonists
Prior art date: 2004-12-22

Application number

CR9266A

Other languages

English (en)

Inventor

T O'neil Karyn

O'neil John

Picha Kristen

Xu Gang

Lark Michael

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2007-07-20

Publication date

2008-09-09

2007-07-20 Application filed by Centocor Inc filed Critical Centocor Inc

2008-09-09 Publication of CR9266A publication Critical patent/CR9266A/es

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
General Physics & Mathematics (AREA)
Toxicology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

CR9266A 2004-12-22 2007-07-20 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos CR9266A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63831304P	2004-12-22	2004-12-22

Publications (1)

Publication Number	Publication Date
CR9266A true CR9266A (es)	2008-09-09

Family

ID=37962937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9266A CR9266A (es)	2004-12-22	2007-07-20	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Country Status (17)

Country	Link
US (1)	US20070128193A1 (es)
EP (1)	EP1843788A4 (es)
JP (1)	JP2008525477A (es)
KR (1)	KR20070090036A (es)
CN (1)	CN101415439A (es)
AU (1)	AU2005337493A1 (es)
BR (1)	BRPI0519241A2 (es)
CA (1)	CA2592065A1 (es)
CR (1)	CR9266A (es)
EA (1)	EA200701362A1 (es)
IL (1)	IL183940A0 (es)
MX (1)	MX2007007602A (es)
NI (1)	NI200700158A (es)
NO (1)	NO20073814L (es)
SG (1)	SG158158A1 (es)
WO (1)	WO2007046834A2 (es)
ZA (1)	ZA200706030B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US20090305964A1 (en) *	2005-04-21	2009-12-10	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
US20070148140A1 (en) *	2005-12-28	2007-06-28	Zoltan Laboratories Llc	Compositions and methods to enhance viability and function of islet cells
IN2015DN00888A (es)	2006-02-22	2015-07-10	Mannkind Corp
AR064623A1 (es) *	2006-12-21	2009-04-15	Centocor Inc	Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
WO2008092209A1 (en) *	2007-02-01	2008-08-07	Arana Therapeutics Limited	Protein construct with improved properties
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
MX2011003277A (es) *	2008-10-14	2012-09-21	Salubrious Pharmaceuticals LLC	Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
PT2373681T (pt)	2008-12-10	2017-04-11	Glaxosmithkline Llc	Composições farmacêuticas de albiglutida
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
US8691763B2 (en)	2010-05-04	2014-04-08	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
WO2012098187A1 (en) *	2011-01-19	2012-07-26	Novo Nordisk A/S	Glp-1 compositions
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
US9950038B2 (en)	2011-08-05	2018-04-24	The Trustees Of The Universiy Of Pennsylvania	Methods and compositions for inhibiting delayed graft function
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2013128450A1 (en) *	2012-03-01	2013-09-06	Yeda Research And Development Co. Ltd.	Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
UA117480C2 (uk)	2013-04-03	2018-08-10	Санофі	Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3229828B1 (en)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
WO2016174130A1 (en) *	2015-04-28	2016-11-03	Université De Strasbourg	Clinical gene signature-based human cell culture model and uses thereof
CN105504026B (zh) *	2015-12-24	2018-12-07	广东医科大学	一种pac1-r和glp-1r的双向激动剂ot23及应用
EP3470424B1 (en) *	2016-06-08	2025-04-23	Shanghai Jiao Tong University School of Medicine	Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
AU2021285138A1 (en)	2020-06-03	2023-02-02	Københavns Universitet	GLP1R agonist NMDAR antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US7241733B2 (en) *	2002-06-28	2007-07-10	Centocor, Inc.	Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
US20070135338A1 (en) *	2004-03-31	2007-06-14	Karyn O'neil	Human GLP-1 mimetibodies, compositions, methods and uses

2005
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown

Also Published As

Publication number	Publication date
CA2592065A1 (en)	2007-04-26
WO2007046834A2 (en)	2007-04-26
WO2007046834A3 (en)	2009-06-18
NO20073814L (no)	2007-09-14
IL183940A0 (en)	2007-10-31
BRPI0519241A2 (pt)	2009-01-06
EP1843788A2 (en)	2007-10-17
AU2005337493A1 (en)	2007-04-26
MX2007007602A (es)	2007-12-07
EP1843788A4 (en)	2009-11-18
NI200700158A (es)	2008-05-13
JP2008525477A (ja)	2008-07-17
KR20070090036A (ko)	2007-09-04
CN101415439A (zh)	2009-04-22
EA200701362A1 (ru)	2008-08-29
US20070128193A1 (en)	2007-06-07
ZA200706030B (en)	2009-12-30
SG158158A1 (en)	2010-01-29

Legal Events

Date	Code	Title	Description
2012-09-20	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR9266A (es)	2008-09-09	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos
CR8706A (es)	2009-01-16	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos, usos
CR10619A (es)	2009-06-04	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
RS20120139A3 (en)	2015-02-27	8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
FR2900573B1 (fr)	2014-05-16	Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
PT1971366E (pt)	2014-11-06	Anticorpos humanos anti-il-23, composições, métodos e usos
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
TWI347313B (en)	2011-08-21	Novel substituted phenoxyacetic acids,pharmaceutical composition comprising them,and use thereof
ME01942B (me)	2015-05-20	Jedinjenja, preparati i metode
FR2885904B1 (fr)	2007-07-06	Nouveaux derives du fluorene, compositions les contenant et utilisation
BRPI0719497A2 (pt)	2014-02-18	"composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
DK1827412T3 (da)	2014-02-10	Sammensætninger til anvendelse i kirurgi
DK2158281T3 (da)	2013-10-14	Farvepigmenteret laksammensætning med høj dækkeevne, forøget ridsefasthed, og let-at-rengøre egenskaber
ITMI20020189A0 (it)	2002-02-01	Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
DE602005012006D1 (de)	2009-02-12	Haarkosmetische Zusammensetzung
DE602005021571D1 (de)	2010-07-15	Haarkosmetische Zusammensetzung
EP1683510A4 (en)	2010-02-17	COSMETIC COMPOSITION
ITRM20060367A1 (it)	2008-01-14	Muteine del hngf usi terapeutici e composizioni farmaceutiche
DK1812120T3 (da)	2015-07-27	Hudbeskyttende, alkalinitetskontrollerende præparat og anvendelsen deraf
DK1784174T3 (da)	2012-12-10	Famaceutisk sammensætning omfattende gabapentin
IL186307A0 (en)	2008-01-20	Human glp-1 mimetibodies, compositions, methods and uses
FR2861290B1 (fr)	2006-02-10	Composition cosmetique thermogonflante.
FR2863874B1 (fr)	2006-03-17	Composition demaquillante
CL2004000184A1 (es)	2005-04-22	Forma polimorfa cristalina del monohidrato de 4-ciclopentilresorcinol, composicion farmaceutica y su uso para reducir la pigmentacion.